Microdialysis combined with UPLC–MS/MS method for determination of tetramethylpyrazine and ferulic acid in striatum of awake and anesthetic rats subjected to cerebral ischemia

Liao, Weiguo; Yu, Jianye; Zhong-lin, Guo; Ba, Wenqiang; Wang, Ding; Zhou, Li; Fan, Wentao; Liao, Fengyun; Wu, Yinai; Wang, Lisheng

doi:10.1016/j.jpba.2016.06.030

Cited by 7 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TMP, a common active ingredient of Ligusticum chuanxiong Hort, has been widely used in the treatment of ischemic cerebrovascular disease (Xu, Shi, & Guan, ). It has been reported that TMP has a good curative effect on ischemic brain injury through reduction of neuronal apoptosis and improvement of brain microcirculation (Kao et al, ; Liao et al, ). Borneol (BO), an active ingredient originating from the resin of Dipterocarpus aromatica Gaertn.…”

Section: Introductionmentioning

confidence: 99%

In vivo microdialysis with ultra performance liquid chromatography–mass spectrometry for analysis of tetramethylpyrazine and its interaction with borneol in rat brain and blood

Liao

Huang

Yin

et al. 2018

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

Tetramethylpyrazine (TMP) has been widely used in the treatment of ischemic cerebrovascular disease. However, the mechanism of TMP and how to increase its bioavailability need to be further explored. In our study, an in vivo microdialysis sampling technique coupled with ultra-performance liquid chromatography-mass spectrometry method was developed to investigate the pharmacokinetic properties of TMP and its interaction with different doses of borneol (BO) in rats. Linearity of TMP in brain and blood dialysates exhibited good linear relationships over the concentration range of 0.991-555.14 ng/mL. The specificity, linearity, accuracy, precision, matrix effect and stability were within acceptable ranges. The results demonstrated that BO had a marked impact on the pharmacokinetic properties of TMP. After co-administration, the areas under the concentration-time curve (AUC) of TMP in brain and blood were significantly increased. Meanwhile, the peak concentration of TMP in brain was also enhanced. The AUC /AUC of TMP, increased from 44% to 56 and 60.8% after co-administration with BO (15 and 30 mg/kg). The pharmacodynamic results showed that TMP co-administration with BO enhanced the cerebral blood flow during the period of ischemia and reduced the infarct volume. Overall, it might be an effective way to treat stroke to use TMP co-administered with BO.

show abstract

Section: Introductionmentioning

confidence: 99%